---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014951"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:52:30.316302+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics director Allan Camaisa to step down at 2026 annual meeting; Board reduced to 5

## Summary
- Director Allan J. Camaisa will not stand for re-election; term expires at 2026 annual meeting; no disagreement with company.
- Board reduced from six to five directors effective at the 2026 annual meeting.
- Scott Leftwich appointed to Audit Committee effective April 1, 2026.
- Camaisa's departure is not due to any disagreement with company operations or policies.

## SEC filing metadata
- accession: 0001493152-26-014951
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315226014951/0001493152-26-014951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315226014951/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014951
- JSON: https://secwatch.observer/filing/0001493152-26-014951.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.